Candriam S.C.A. Has $61.10 Million Position in BioNTech SE Sponsored ADR $BNTX

Key Points

• Candriam S.C.A. reduced its stake in BioNTech SE by 20.8%, selling 175,979 shares and now owning approximately 0.28% of the company, valued at $61.1 million.
• BioNTech reported earnings of ($1.60) per share for the most recent quarter, missing analysts' estimates, but achieved 102.6% year-over-year revenue growth with $306.46 million in revenue.
• Analyst ratings for BioNTech show a consensus of "Moderate Buy" with a target price averaging $135.80, reflecting a mix of upward and downward adjustments from various research firms.

Candriam S.C.A. cut its stake in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 20.8% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 670,955 shares of the company's stock after selling 175,979 shares during the quarter. Candriam S.C.A. owned approximately 0.28% of BioNTech worth $61,098,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in BNTX. Geode Capital Management LLC grew its holdings in shares of BioNTech by 1.1% during the fourth quarter. Geode Capital Management LLC now owns 101,715 shares of the company's stock valued at $11,590,000 after purchasing an additional 1,063 shares during the last quarter. Raymond James Financial Inc. bought a new position in shares of BioNTech during the fourth quarter valued at approximately $584,000. CANADA LIFE ASSURANCE Co boosted its position in shares of BioNTech by 63.5% during the fourth quarter. CANADA LIFE ASSURANCE Co now owns 7,791 shares of the company's stock worth $887,000 after buying an additional 3,025 shares during the period. Tower Research Capital LLC TRC boosted its position in shares of BioNTech by 61.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,881 shares of the company's stock worth $214,000 after buying an additional 713 shares during the period. Finally, Diadema Partners LP acquired a new position in shares of BioNTech during the fourth quarter worth approximately $999,000. 15.52% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on BNTX shares. Bank of America boosted their price objective on BioNTech from $126.00 to $134.00 and gave the stock a "buy" rating in a research report on Tuesday, August 5th. Wells Fargo & Company set a $150.00 price objective on BioNTech and gave the stock an "overweight" rating in a research report on Tuesday, August 5th. Morgan Stanley boosted their price objective on BioNTech from $132.00 to $133.00 and gave the stock an "overweight" rating in a research report on Thursday, July 10th. Leerink Partners set a $112.00 price objective on BioNTech in a research report on Monday, June 2nd. Finally, JPMorgan Chase & Co. cut their target price on BioNTech from $120.00 to $116.00 and set a "neutral" rating for the company in a research report on Thursday, May 22nd. Thirteen analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $135.80.

BioNTech Price Performance

Shares of NASDAQ:BNTX traded down $3.7650 on Monday, reaching $107.1150. 629,268 shares of the company traded hands, compared to its average volume of 924,191. BioNTech SE Sponsored ADR has a fifty-two week low of $81.20 and a fifty-two week high of $131.49. The company's 50 day moving average is $109.90 and its 200-day moving average is $105.38. The stock has a market capitalization of $25.75 billion, a PE ratio of -66.91 and a beta of 1.23. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.61 and a quick ratio of 8.48.

BioNTech (NASDAQ:BNTX - Get Free Report) last announced its quarterly earnings data on Monday, August 4th. The company reported ($1.60) EPS for the quarter, missing analysts' consensus estimates of ($1.41) by ($0.19). BioNTech had a negative net margin of 12.20% and a negative return on equity of 1.84%. The company had revenue of $306.46 million for the quarter, compared to analyst estimates of $161.26 million. During the same quarter last year, the company posted ($3.36) EPS. BioNTech's revenue was up 102.6% on a year-over-year basis. BioNTech has set its FY 2025 guidance at EPS. As a group, analysts anticipate that BioNTech SE Sponsored ADR will post -3.88 earnings per share for the current fiscal year.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.